Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in Metastatic Osteosarcoma
NCT00023998Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Nov 2005
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in osteosarcoma (OS) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Feasibility and safety of trastuzumab and chemotherapy up to 6 years, Response rate up to 6 years and 3 more. Started Jul 2001; status: completed.
02
Drugs
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00023998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023998.